AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 31.9% according to Barclays.
Barclays set a target price of 13,500 GBX for the company, which when compared to the AstraZeneca plc share price of 10,238 GBX at opening today (22/11/2023) indicates a potential upside of 31.9%. Trading has ranged between 10,012 (52 week low) and 12,828 (52 week high) with an average of 1,726,935 shares exchanging hands daily. The market capitalisation at the time of writing is £156,944,291,640.
AstraZeneca PLC is a science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory and immunology. Its pipeline forms a portfolio of investigational therapies in various stages of clinical development and includes the Alexion Rare Disease portfolio comprising approximately 178 projects. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its BioPharmaceuticals products include Farxiga, Lokelma, Crestor, Breztri and others. Its geographical segments include United Kingdom, Rest of Europe, the Americas and Asia, Africa and Australasia. It is also focused on discovering, developing, and manufacturing of T-cell receptor therapies.
AstraZeneca plc 31.9% potential upside indicated by Barclays
- Written by: Charlotte Edwards
Latest Company News
AstraZeneca reported first-half 2026 revenue of $30.7 billion, up 6% at constant exchange rates, with core operating profit and core EPS both rising 11%. Growth in oncology and rare disease offset Farxiga and China headwinds. The company raised its interim dividend, secured 30 approvals, and reaffirmed full-year guidance and its $80 billion 2030 revenue goal.
Astrazeneca Plc has reported statistically significant overall survival results for Sone-Ve in the CLARITY-Gastric01 Phase III trial.
Astrazeneca Plc has secured European Union approval for Etcamah in combination therapy for ER-positive, HER2-negative advanced breast cancer.
Astrazeneca Plc has agreed an exclusive licence with Dizal Pharmaceutical for Zegfrovy, adding a novel oral EGFR inhibitor to its oncology portfolio.
The CARDIO-TTRansform Phase III trial1 for AstraZeneca and Ionis' Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy...
Astrazeneca Plc says CHMP has recommended Datroway for EU approval as first-line treatment in metastatic triple-negative breast cancer.
